Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

artículo científico publicado en 2020

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.

artículo científico publicado en 2018

Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles

artículo científico

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

artículo científico publicado en 2018

Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-2

artículo científico publicado en 2020

Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

artículo científico publicado en 2018

Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib

scientific article published on 17 September 2020

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center

artículo científico publicado en 2015

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

scientific article published on 19 November 2019

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

scientific article published on 17 September 2018

Genomic predictors of good outcome, recurrence or progression in High grade T1 non-muscle invasive bladder cancer

scientific article published on 31 August 2020

Impact of primary tumor location on survival from EORTC advanced urothelial cancer studies.

artículo científico publicado en 2017

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect

scientific article published on 11 July 2019

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

artículo científico publicado en 2014

Management of metastatic bladder cancer

artículo científico publicado en 2019

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials

scientific article published on 07 September 2018

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.

artículo científico publicado en 2017

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

scientific article published on 12 May 2014

Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models

artículo científico publicado en 2019

Randomised phase II study comparing alternating cycles of sunitinib and everolimus versus standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)

scientific article published on 12 July 2020

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer

artículo científico publicado en 2021

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability

scientific article published on 07 March 2019

Treatment of Metastatic Urothelial Cancer in 2018

scientific article published on 01 June 2019

Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study

scientific article published on 08 February 2020

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.

Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-2

Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

Genomic predictors of good outcome, recurrence or progression in High grade T1 non-muscle invasive bladder cancer

Impact of primary tumor location on survival from EORTC advanced urothelial cancer studies.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Management of metastatic bladder cancer

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models

Randomised phase II study comparing alternating cycles of sunitinib and everolimus versus standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability

Treatment of Metastatic Urothelial Cancer in 2018

Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study